STING agonist-9 

STING agonist-9 (Compound 45) is a potent STING agonist with an EC₅₀ of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity^[1].

EC₅₀: 1.2 nM (h-STING), 32.82 μM (m-STING)^[1]

STING agonist-9 (Compound 45) directly binds to various h-STING isoforms and m-STING^[1].
STING agonist-9 potently activates both ISG and NF-κB signaling pathways^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

STING agonist-9 (Compound 45) significantly inhibits the tumor growth in allograft 4T1 and CT26 tumor models by systemic administration, and induces tumor regression in CT26 tumor model without inducing weight loss^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

825.94

C₃₉H₄₇N₁₃O₆S

2653337-73-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Niu J, et al. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration. Eur J Med Chem. 2022 Aug 5;238:114482.  [Content Brief]